Market cap
₹259 Cr
Revenue (TTM)
₹45 Cr
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
259 | 20,853 | 20,665 | 17,907 | 16,905 |
Revenue (₹ Cr) |
45 | 2,287 | 1,682 | 2,570 | 3,230 |
Net Profit (₹ Cr) |
-2.52 | 678.07 | 273.51 | 735.15 | 666.92 |
Net Margin (%) |
-5.39 | 28.10 | 16.19 | 26.88 | 20.60 |
RoE (%) |
-2.55 | 19.73 | 11.15 | 19.16 | 18.75 |
Price to Earnings |
-- | 31.34 | 69.51 | 24.36 | 26.25 |
Price-To-Book |
2.74 | 5.68 | 7.69 | 4.06 | 4.19 |
Income Statement (₹ Cr)
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
43.61 | 2,187.19 | 1,538.87 | 2,519.65 | 3,129.42 |
|
Total Income
|
45.92 | 2,302.73 | 1,602.52 | 2,707.60 | 3,147.87 |
|
Total Expenditure
|
34.43 | 1,426.34 | 1,157.98 | 1,615.47 | 2,020.01 |
|
EBITDA
|
9.19 | 760.85 | 380.89 | 904.18 | 1,109.41 |
|
Depreciation
|
7.11 | 72.77 | 119.72 | 57.73 | 279.50 |
|
EBIT
|
2.08 | 688.08 | 261.17 | 846.45 | 829.91 |
|
Interest
|
-- | 0.87 | 58.79 | 9.57 | 192.67 |
|
Other Income
|
2.31 | 115.54 | 63.65 | 187.95 | 18.45 |
|
Exceptional Items
|
-0.20 | -- | 12.16 | -49.16 | -17.24 |
|
Profit before Tax
|
4.19 | 802.79 | 295.31 | 975.67 | 638.54 |
|
Provision for Tax
|
5.26 | 153.06 | 51.98 | 253.24 | -8.97 |
|
Profit after Tax
|
-1.07 | 649.73 | 243.33 | 722.43 | 647.51 |
Liabilities (₹ Cr)
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
95.12 | 3,586.42 | 2,591.20 | 4,202.90 | 3,902.67 |
|
Minority Interest
|
-- | 44.38 | 1.04 | -- | -7.01 |
|
Non-Current Liabilities
|
3.98 | 20.75 | 249.46 | 19.19 | 1,149.84 |
|
Current Liabilities
|
12.06 | 385.96 | 848.06 | 627.48 | 2,201.22 |
|
Total Liabilities
|
111.15 | 4,037.51 | 3,705.61 | 4,921.88 | 7,246.72 |
Assets (₹ Cr)
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
70.11 | 1,451.85 | 2,578.95 | 1,046.35 | 5,582.75 |
|
Current Assets
|
41.04 | 2,585.66 | 1,109.77 | 3,803.22 | 1,663.97 |
|
Total Assets
|
111.15 | 4,037.51 | 3,705.61 | 4,921.88 | 7,246.72 |
|
Total Debt*
|
0.00 | 0.57 | 657.97 | 2.50 | 2,309.68 |
|
Net Current Assets
|
28.98 | 2,199.70 | 261.71 | 3,175.74 | -537.25 |
|
Contingent Liabilities
|
1.05 | 17.53 | 160.01 | 370.49 | 51.57 |
Cashflow (₹ Cr)
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
10.20 | 523.24 | 342.18 | 967.57 | 537.99 |
|
Cash Flow from Investing Activities
|
-6.49 | -582.30 | -325.92 | -561.67 | -369.46 |
|
Cash from Financing Activities
|
-- | -46.46 | 13.62 | -798.31 | -313.53 |
|
Net Cash Inflow / Outflow
|
3.71 | -105.52 | 29.88 | -392.41 | -145.00 |
Ratios
Profitability Ratios
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
4.38 | 24.97 | 11.43 | 23.39 | 14.47 |
|
ROE (%)
|
-1.12 | 20.79 | 9.82 | 17.16 | 19.23 |
|
ROA (%)
|
-0.98 | 17.94 | 6.97 | 14.91 | 9.18 |
|
EBIT Margin (%)
|
26.36 | 40.07 | 28.89 | 43.34 | 36.04 |
|
Net Margin (%)
|
-2.33 | 28.22 | 15.18 | 26.68 | 20.57 |
|
Cash Profit Margin (%)
|
13.85 | 33.03 | 23.59 | 29.72 | 28.49 |
Growth Ratios
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.32 | 12.89 | 19.62 | 10.45 | 8.15 |
|
EBIT Growth (%)
|
-26.90 | 17.90 | 29.72 | 19.68 | 8.91 |
|
Net Profit Growth (%)
|
-119.10 | 20.08 | 210.81 | -5.88 | 72.82 |
|
EPS Growth (%)
|
-119.10 | 19.57 | 210.80 | -5.88 | 73.16 |
|
Book Value Growth (%)
|
-1.05 | 26.75 | 9.67 | -0.34 | 36.71 |
Valuation Ratios
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 17.84 | 28.03 | 29.89 | 29.02 |
|
Price / Book Value
|
2.20 | 3.27 | 2.63 | 5.14 | 4.62 |
|
Dividend Yield (%)
|
0.00 | 0.53 | 0.17 | 1.59 | 0.00 |
|
EV/EBITDA
|
15.56 | 12.43 | 16.72 | 16.93 | 17.93 |
|
Market Cap (₹ Cr)
|
209.28 | 11,439.22 | 6,819.66 | 21,592.90 | 17,980.08 |
Solvency Ratios
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.25 | 0.00 | 0.59 |
|
Short term debt to equity ratio
|
-- | 0.00 | 0.16 | 0.00 | 0.12 |
|
Current Ratio
|
3.40 | 6.70 | 1.31 | 6.06 | 0.76 |
|
Quick Ratio
|
3.40 | 5.59 | 0.88 | 5.31 | 0.56 |
|
Interest Coverage
|
-- | 923.75 | 6.02 | 102.95 | 4.31 |
Operating Efficiency Ratios
| Zenotech Lab | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.12 | 37.76 | 33.72 | 7.22 | 21.74 |
|
Asset Turnover
|
0.40 | 0.60 | 0.44 | 0.54 | 0.46 |
|
Receivable days
|
67.92 | 121.68 | 113.81 | 26.06 | 63.88 |
|
Inventory Days
|
0.00 | 63.83 | 84.76 | 65.95 | 43.27 |
|
Payable days
|
1,263.19 | 108.28 | 101.94 | 81.01 | 151.85 |
|
Cash Conversion Cycle
|
-1,217.81 | 77.23 | 96.62 | 11.00 | -44.70 |